Premium
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate
Author(s) -
Aboud Ambrose,
Buzdar Aman U.,
Yap HweeYong,
Hortobagyi Gabriel N.,
Blumenschein George R.
Publication year - 1984
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930260315
Subject(s) - medicine , cyclophosphamide , methotrexate , fluorouracil , chemotherapy , metastatic breast cancer , oncology , breast cancer , toxicity , surgery , cancer , gastroenterology
Twenty‐nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response rate was 75%. The median survival from initiation of chemotherapy for the responding patients was 18 months. Four patients (17%) with stable disease had a median survival of 25 months. The addition of MTX to FAC chemotherapy did not improve the therapeutic efficacy of this combination; it did, however, increase the overall toxicity, especially the infectious complications when compared to FAC alone.